Because TNF-α and IL-1 β production were substantially and long-term inhibited during IL-10 treatment, it was previously tested in the clinical treatment of inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease (Wang et al., 2019). This evidence concerns the gene IL10 and psoriasis.